Predictions
Canopy Growth Corp
Start price
Target price
Perf. (%)
€8.47
13.12.21
13.12.21
-
13.12.22
13.12.22
-67.06%
14.12.22
14.12.22
Could be very worthwhile Investment >20% year
Revenue decline/stagnation expected
Mirati Therapeutics Inc.
Start price
Target price
Perf. (%)
€47.20
07.12.22
07.12.22
-
07.12.23
07.12.23
-16.53%
10.12.22
10.12.22
Risky Investment
Canopy Growth Corp
Start price
Target price
Perf. (%)
€2.55
13.10.22
13.10.22
€2.30
13.10.23
13.10.23
42.55%
19.11.22
19.11.22
Lower EBIT Margin than peer group
High valuation
Very low/no dividend yield expected
Risky balance sheet
Canopy Growth Corp
Start price
Target price
Perf. (%)
€13.55
13.11.21
13.11.21
-
13.11.22
13.11.22
-69.88%
14.11.22
14.11.22
Could be worthwhile Investment >10% per year
Revenue growth >5% per year expected
Innovative
Future proof or reliable business model
Orpea Nom.
Start price
Target price
Perf. (%)
€9.52
26.10.22
26.10.22
-
26.10.23
26.10.23
-30.01%
30.10.22
30.10.22
Could be very worthwhile Investment >20% year
Orpea Nom.
Start price
Target price
Perf. (%)
€7.95
28.10.22
28.10.22
-
28.10.23
28.10.23
-16.20%
29.10.22
29.10.22
Could be very worthwhile Investment >20% year
Korian S.A.
Start price
Target price
Perf. (%)
€28.30
17.10.21
17.10.21
€30.00
17.10.22
17.10.22
-62.44%
18.10.22
18.10.22
Could be worthwhile Investment >10% per year
Galapagos N.V.
Start price
Target price
Perf. (%)
€45.08
13.10.21
13.10.21
€46.00
13.10.22
13.10.22
-0.18%
14.10.22
14.10.22
Could be worthwhile Investment >10% per year
Galapagos N.V.
Start price
Target price
Perf. (%)
€45.08
13.10.21
13.10.21
€46.00
13.10.22
13.10.22
-0.18%
14.10.22
14.10.22
Could be worthwhile Investment >10% per year
Canopy Growth Corp
Start price
Target price
Perf. (%)
€2.91
03.08.22
03.08.22
€3.30
03.08.23
03.08.23
-12.37%
13.10.22
13.10.22
Lower EBIT Margin than peer group
High valuation
Very low/no dividend yield expected
Risky balance sheet
Orpea Nom.
Start price
Target price
Perf. (%)
€101.00
28.09.21
28.09.21
€105.00
28.09.22
28.09.22
-87.18%
29.09.22
29.09.22
Could be worthwhile Investment >10% per year
MorphoSys AG
Start price
Target price
Perf. (%)
€30.80
08.01.22
08.01.22
-
08.01.26
08.01.26
-46.20%
05.09.22
05.09.22
Probably not worthwhile Investment
MorphoSys AG
Start price
Target price
Perf. (%)
€30.80
08.01.22
08.01.22
-
08.01.26
08.01.26
-46.20%
05.09.22
05.09.22
Probably not worthwhile Investment
Mirati Therapeutics Inc.
Start price
Target price
Perf. (%)
€76.50
21.08.22
21.08.22
€230.00
21.08.23
21.08.23
6.54%
04.09.22
04.09.22
Revenue growth >5% per year expected
EBIT growth >5% per year expected
Probably not worthwhile Investment
Lower EBIT Margin than peer group
Alnylam Pharmace.
Start price
Target price
Perf. (%)
€214.90
21.08.22
21.08.22
€87.00
21.08.23
21.08.23
-3.44%
04.09.22
04.09.22
Probably not worthwhile Investment
Revenue decline/stagnation expected
EBIT decline/stagnation expected
Lower EBIT Margin than peer group
Tandem Diabetes Care Inc
Start price
Target price
Perf. (%)
€91.50
10.08.21
10.08.21
-
10.08.22
10.08.22
-42.25%
10.08.22
10.08.22
Global Blood Therapeutics Inc
Start price
Target price
Perf. (%)
€33.09
30.10.21
30.10.21
€45.00
31.12.23
31.12.23
94.65%
05.08.22
05.08.22
Could be very worthwhile Investment >20% year